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Background: Recent studies have shown adjuvant therapy improves outcomes from pancreatic cancer
(PC). This study investigates receipt and timing of PC treatments, and association with outcomes.
Methods: The analysis cohort consisted of patients with newly-diagnosed PC at a single institution over
5 years. Primary Endpoints were (i) receipt of recommended therapy, and (ii) overall survival (OS).
Results: Among 102 patients, 52 underwent resection. Out of 36 localized resected and 16 locally
advanced resected (LAR) patients, 26 and 13, respectively, received adjuvant therapy. Six of the latter
group received neoadjuvant therapy. Median OS for resected patients was 15.7 months (range 0.6–51.4),
compared with 7.7 for unresected patients (range 0.4–32.0) (P < 0.001), and 14.0 months for patients with
resection alone (range 0.6–24.4) vs. 16.1 for patients who also received adjuvant therapy (range 3.2–51.4)
(P = 0.027). Out of 46 patients undergoing up-front resection, 33 had R0 surgical margins. For the six LAR
patients undergoing neoadjuvant therapy, all margins were R0.
Conclusion: After resection, a substantial proportion of patients do not receive adjuvant therapy, and
have worse survival. In this study, neoadjuvant treatment increased both the proportion of patients
receiving all components of recommended therapy and the R0 resection rate.
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Introduction
Improving outcomes for patients diagnosed with pancreatic
cancer continues to be a formidable challenge. In the year 2008,
there will be an estimated 32 180 patients with newly diagnosed
pancreatic cancer in the United States,1 where the disease ranks
fourth among the leading causes of cancer-related death.2,3 Even
with aggressive treatment, prognosis remains extremely poor, with
less than 5% of patients surviving 5 years beyond diagnosis.2
The high rate of mortality from pancreatic cancer is multifac-
torial. Progression to advanced disease prior to diagnosis, biologi-
cal aggressiveness of the tumours and a continuing lack of
adequate systemic therapies have all been implicated as important
contributing factors.4 Currently, only treatment approaches that
include surgical resection offer any potential for long-term
survival.3 Unfortunately, only 15% to 20% of patients present with
tumours amenable to resection.5 Even in patients who do undergo
resection for localized pancreatic carcinoma, the majority of
patients will have relapse of disease.6
Recent studies have shown that adjuvant therapy can further
improve outcomes in patients who have undergone pancrea-
tectomy for pancreatic adenocarcinoma.7–16 While the role of
adjuvant chemoradiotherapy vs. chemotherapy-alone remains
controversial in light of the mixed results of the Gastrointestinal
Tumor Study Group (GITSG) and European Study Group for
Pancreatic Cancer (ESPAC-1) Trails,9,10,17,18 chemoradiotherapy
remains highly utilized in the United States pending additional
evidence.19 Unfortunately, for a variety of reasons, including
comorbidities, post-operative complications, and patient choice,
not all patients receive recommended adjuvant therapy. Given the
known survival benefit for patients with resectable pancreatic*These authors contributed equally to the manuscript.
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adenocarcinoma, receipt of all recommended treatment compo-
nents is extremely important. This study investigates, at the insti-
tutional level, the frequencies, timing and associated factors, for
when this does or does not occur. We hypothesize that potentially
modifiable factors can be identified and targeted in order to maxi-
mize the proportion of patients ultimately receiving optimized
treatment. Using our institutional prospectively collected data-
base, we examined the factors that influence the receipt of all
components of therapy in patients who had surgical resection for
pancreatic adenocarcinoma.
Patients and methods
Cohort selection criteria
Patients referred to a dedicated surgical oncology service for pos-
sible surgical resection of a pancreatic mass, from June 2002
through to July 2007, were identified from a prospectively main-
tained institutional pancreatic database. For the purposes of this
study, patients with a tissue diagnosis other than pancreatic
adenocarcinoma were excluded, as were those lacking follow-up
data (three patients). The remaining 102 patients formed the
primary cohort, representing those initially considered as poten-
tial candidates for surgical resection, pending further studies to
rule out inoperable disease.
Review of patient data
Patients were categorized by stage according to the American
Joint Committee on Cancer (AJCC) staging definitions for adeno-
carcinoma of the pancreas.20 The clinical and pathological char-
acteristics of patients were obtained by retrospective review
of electronic medical records and paper charts. The study was
approved by the Institutional Review Board.
The following variables were obtained from the database: (i)
patient demographic characteristics (age and gender), (ii) diag-
nostic and staging variables, (iii) operative procedure (pancreati-
coduodenectomy or ‘Whipple procedure’, total pancreatectomy,
distal pancreatectomy and proximal pancreatectomy), (iv) stage
at presentation (localized, borderline resectable, locally unresect-
able and metastatic disease) and (v) type of combined modality
therapy (neoadjuvant vs. adjuvant).
The primary endpoints for the study were percentage of
patients completing components of recommended therapy and
overall survival. Length of survival was calculated from the date
of initial surgical diagnostic evaluation until date of death.
Clinical staging and resection criteria
Diagnostic and clinical staging evaluations for all patients
included physical examination, routine laboratory testing, chest
radiography and contrast-enhanced computed tomography (CT).
The majority of patients also underwent endoscopic ultrasound
(EUS) and had their management discussed at a weekly multi-
disciplinary tumour board. After initial diagnostic work-up,
patients without clearly unresectable disease also underwent
staging laparoscopy. Tumour resectability was determined by the
surgical oncologist, based on the following specific clinical staging
criteria:21,22
1 Localized resectable disease: (i) no extrapancreatic disease, (ii) a
patent superior mesenteric (SMV)-portal vein (PV) confluence
(assuming the technical ability to resect and reconstruct this
venous confluence) and (iii) a definable tissue plane between
the tumour and regional arterial structures including the celiac
axis, common hepatic artery and SMA.
2 Borderline resectable disease: (i) no extrapancreatic disease
and (ii) the following possible tumour-vessel relationships: an
SMV-PV confluence that can be reconstructed even if short
segment venous occlusion is present, tumour abutment of the
SMA of 180° or short segment encasement of the hepatic
artery amenable to resection and reconstruction.
3 Locally advanced unresectable disease: (i) no extrapancreatic
disease and (ii) tumour encasement of the SMA or celiac
axis defined as tumour involvement of >180° of the arterial
circumference.
4 Metastatic disease: radiographical, clinical or staging laparo-
scopic evidence of distant organ or peritoneal metastases.
Classification of combined modality therapy
Data regarding treatment with chemo- and/or radiotherapy were
obtained from the medical records. Treating physician offices were
contacted for additional information when appropriate. Adjuvant
chemotherapy or chemoradiation was defined as either post-
operative (standard adjuvant) or as pre-operative (neoadjuvant).
Owing to our institutional standard during the time period of this
study, all the patients with localized resectable disease were offered
up-front surgery with standard post-operative adjuvant therapy.
Neoadjuvant therapy was offered to a subset of patients with
borderline resectable or locally advanced unresectable disease.
Chemoradiation regimens
Standard adjuvant therapy
All patients undergoing surgical resection were evaluated at a
multi-disciplinary clinic by a medical oncologist and radiation
oncologist. Although the survival benefit of adjuvant chemorad-
iotherapy compared with adjuvant chemotherapy alone remains
controversial in light of the mixed results of important clinical
trials to date (particularly ESPAC-1),9,10,17,18 the majority of insti-
tutions in the United States continue to offer combined modality
adjuvant therapy pending further evidence.19 As such, both adju-
vant chemotherapy and radiotherapy were considered for all
resectable patients in this study.
Radiation treatments were given as external beam radiotherapy,
consisting of 50.4 Gy in 28 fractions. Concomitant chemotherapy
consisted of 5-flurouracil (FU), paclitaxel or capecitabine, at
radio-sensitizing doses. Resected patients beyond the year 2005
who were well enough to receive systemic adjuvant chemotherapy
also received gemcitabine. The majority of those patients were
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treated based on the RTOG 9704 regimen and received 1 month of
gemcitabine followed by chemoradiotherapy followed by 3 more
months of gemcitabine.
Neoadjuvant therapy
Neoadjuvant radiation treatments were also given as 50.4 Gy of
external beam radiotherapy in 28 fractions. Concomitant chemo-
therapy consisted of 5 FU, capecitabine, infusional 5 FU and gem-
citabine. One patient was treated on an in-house protocol using
cetuximab together with infusional 5 FU and gemcitabine.
Clinical restaging was performed 4–6 weeks after neoadjuvant
chemoradiotherapy in preparation for surgical resection. One
patient received additional systemic chemotherapy with gemcit-
abine and erlotinib for 4 months beyond initial restaging, prior
to eventual surgical resection.
Assessment of margin status
Standardized histological evaluation of the surgical specimens was
performed as described by the American Joint Committee on
Cancer.20 Final margins were recorded as negative (R0) or micro-
scopically positive (R1) for tumour. There were no R2 resections
for this cohort. A margin was designated positive if tumour cells
were present at the inked resection margin, retroperitoneal
margin, pancreatic or biliary margins. In addition, specimens
were oriented by the surgeon for assessment of the portal vein
groove whenever there was intra-operative evidence of possible
tumour involvement at that location.
Long-term follow-up and survival
Long-term follow-up and survival data were available for all
patients. Survival data from the medical records was confirmed
using the social security death index. Follow-up was continued
through the end-point of the study, August 2008.
Statistical analysis
SAS 9.1.3 software (SAS Institute, Cary, NC) was used for all
statistical analyses of this study. Kaplan–Meier methods compared
median survival.23 The log-rank test was used to assess differences
between survival curves. Univariate analyses were done using c2
tests to examine the effect of patient and disease characteristics on
patient survival. Statistical significance was set at P < 0.05.
Results
Patient demographics and initial staging
Between 2002 and 2007, 102 patients were referred to our institu-
tion for surgical evaluation of a suspected pancreatic cancer.
Patients ranged in age from 41 to 85 years, with a median age of 65
years. Both genders were diagnosed in similar numbers, with 54
out of 102 (53%) being males. The tumour was located in the head
of the pancreas in 76 patients (75%). Of the 102 patients, 51
patients were initially clinically staged with localized disease
(50%), 23 with locally advanced borderline resectable disease
(22%), 15 with locally advanced unresectable disease (15%) and
13 with preliminary evidence suspicious for metastatic disease
(13%). Patient characteristics for this cohort are outlined in
Table 1.
Neoadjuvant therapy and restaging
A total of 19 patients with locally advanced borderline resectable
or unresectable disease were placed on a neoadjuvant chemoradi-
ation protocol (8 and 11 patients, respectively). Four patients with
locally advanced unresectable disease were subsequently restaged
to resectable after neoadjuvant therapy. One patient with border-
line resectable disease at the time of starting neoadjuvant therapy
had progression of disease to metastasis. Cancer staging for this
cohort is shown in Table 2.
Pancreatic resection and resection margins
Out of the 102 patients diagnosed with pancreatic adenocarci-
noma and evaluated for surgery, 58 patients (57%) (39 localized
and 19 borderline resectable) under went surgery with curative
intent. Of the remainder, 35 had locally advanced unresectable
or metastatic disease, 6 were poor surgical candidates owing to
co-morbid disease and 3 decided against recommended surgery.
Six patients who under went surgery with curative intent (10%)
were found at the time of laparotomy to have unresectable and/or
metastatic disease. Pancreatic resection was performed on 52
patients (36 localized resectable and 16 borderline resectable).
Resected patients underwent standard pancreaticoduodenectomy
Table 1 Patient characteristics (n = 102)
Age (years)
Range 41–85
Median 65
Gender
Male 54 (52.9%)
Female 48 (47.1%)
Location
Head 76 (74.5%)
Body 7 (6.9%)
Tail 11 (10.8%)
Multi-focal 8 (7.8%)
Staging laparoscopy
No 41 (40.2%)
Yes 61 (59.8%)
Resection
No 50 (49.0%)
Yes 52 (51.0%)
Adjuvant therapy
Standard post-operative 33 (63.5% of resected group)
Neoadjuvant 6 (11.5% of resected group)
Neither 13 (25.0% of resected group)
Unresected 50
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(Whipple procedure) (29), pylorus-sparing Whipple procedure
(10), distal pancreatectomy (9) or total pancreatectomy (4).
Surgical resection margins were microscopically negative for
tumour cells in 39 out of the 52 resections. All 36 resected patients
with localized disease had traditional up-front surgery, and of
those, 28 had R0 resections. Out Of 16 patients with borderline
resectable disease, 11 had R0 resections. There was no significant
difference in R0 rate between these two groups (Fisher’s exact test
P = 0.506). Of those patients with borderline resectable disease
having traditional up-front surgery (10), five had R0 resections. In
contrast, all six patients with locally advanced borderline resect-
able disease who had received neoadjuvant therapy had R0 resec-
tions (Fisher’s exact test P  0.093). Resected margin status
information is provided in Table 3.
Adjuvant therapy
Of resected patients with localized disease (36), 26 received
adjuvant therapy, all by a standard post-operative approach. The
median time from surgical resection to initiation of standard
post-operative adjuvant therapy was 79 days (range 33–175).
Thirteen patients out of 16 with resected locally advanced disease
received additional therapy. Nearly half of them (6 of 13) received
it according to a neoadjuvant protocol. The distribution of
resected patients by stage and treatment received is shown in
Fig. 1.
Completion of therapy
Of patients with localized disease, 17 out of 36 completed
scheduled adjuvant therapy; none received neoadjuvant therapy.
In contrast, 13 out of 16 of the borderline group completed
chemoradiation as planned. Nearly half of these (6 of 13) received
up-front neoadjuvant rather than traditional post-operative
therapy. Reasons for not completing recommended therapy
included surgical or medical complications, disease progression,
and patient preference.
Complications
Post-operative complications occurred in 27 out of 52 patients
who underwent resection. Major complications included haem-
orrhage (2), leak or abscess (2), cardiopulmonary-related compli-
cations (2), wound infections (3), neurological complications
(1) and prolonged gastric emptying (2). In addition, there were 15
other minor complications (15). Peri-operative death occurred
in three patients (6%). Reported chemoradiotherapy-related
Table 2 Tumour staging (n = 102)
Initial clinical
staging
Clinical
restaging
Localized 51 51
Borderline resectable 23 26*
Locally unresectable 15 11
Metastasis 13 14†
*Four patients diagnostically and/or laparoscopically staged as locally
unresectable who received neoadjuvant therapy were subsequently
restaged to borderline resectable. †One patient diagnostically and/or
laparoscopically staged as borderline resectable who received neoadju-
vant therapy was subsequently restaged to metastatic disease.
Table 3 Resection margin status (n = 52)
Characteristic Frequency
Resection Margin
R0 39
R1 13
Resection margin by stage and treatment
Localized disease 36
R0 28
R1 8
Borderline resectable 16
Upfront surgery 10
R0 5
R1 5
Neoadjuvant therapy 6
R0 6
R1 0
Resected Patients (52) 
Localized (36)
Chemo/RT (26) No Chemo/RT (10) Chemo/RT (13)
Adjuvant (26) Adjuvant (7)
Borderline (16)
No Chemo/RT (3)  
Neoadjuvant (0) Neoadjuvant (6) 
Figure 1 Flow diagram of resected (RT) pancreatic adenocarcinoma patients by treatment approach
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toxicities included: haematological (6), constitutional (5), gas-
trointestinal (8) and gemcitabine-associated skin changes (3).
Survival
The median overall survival for all resected patients was 15.7
months (range 0.6–51.4) compared with 7.7 months for unre-
sected patients (range 0.4–32.0) (log rank P < 0.001). The median
survival for patients who had surgical resection alone was 14.0
months (range 0.6–24.4). In contrast, the median survival for
patients who received combined modality therapy (adjuvant or
neoadjuvant chemoradiation in addition to surgical resection)
was 16.1 months (range 3.2–51.4) (log rank P = 0.027 vs. resection
alone). Kaplan–Meier survival analysis is shown in Fig. 2.
Discussion
The management of patients with resectable pancreatic cancer has
evolved significantly over the past several years, including the
evolution of what constitutes resectability to include patients
with borderline disease. Surgical resection continues to be the
only potential cure for patients with pancreatic adenocarcinoma,24
and while peri-operative mortality has improved dramatically in
recent years,25 long-term survival after resection remains essen-
tially unchanged.
Several recent clinical trials have indicated that adjuvant sys-
temic chemotherapy improves outcome in patients with resected
pancreatic adenocarcinoma.7,8,26 The role of adjuvant radiation
Figure 2 Overall Kaplan-Meier survival of patients with pancreatic adenocarcinoma reffered for surgical evaluation for (A) resected versus
unresected patients and (B) resected patients with or without chemo-radiation
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remains controversial with conflicting results from three impor-
tant clinical trials. However, pending further evidence, it contin-
ues to be the standard of care in the United States.16,27
We report a single-institutional experience of patients with a
presumed pancreatic cancer referred for surgical evaluation.
Access to patient records allowed a more in-depth review of clini-
cal data than is typically possible with larger non-institutional
database studies.
It is quite striking that fewer than three-quarters of the patients
in this study with presumed localized and therefore surgically
resectable disease actually underwent surgical resection (36 of 51).
In addition, of these patients with localized disease that did
undergo resection, 10 did not receive combined modality therapy.
The survival results of this study concur with those of randomized
trials indicating that those who receive combined modality
therapy have a better outcome over surgical resection alone.
In contrast, in patients with borderline resectable disease, 13 of
16 resected patients received combined modality therapy. This is
in part due to the fact that nearly half of these patients receive
neoadjuvant (pre-operative) therapy. Despite small numbers, the
outcome of the patients who received pre-operative therapy
followed by surgical resection is comparable to the patients who
received post-operative therapy. Considering the fact that the
patients who received neoadjuvant therapy were judged to be
borderline resectable and hence by definition had more advanced
disease at presentation, these results are quite encouraging.
Owing to our institutional standard during the time period of
the study, the majority of patients had up-front surgery. Notably,
five patients who had borderline resectable disease (16) who
underwent up-front surgery (10) had resulting positive margins
after resection. In contrast, all six borderline resectable patients
who received neoadjuvant chemoradiotherapy had R0 resections.
Given the small number of patients receiving neoadjuvant therapy
in this cohort, these results are supportive of continued studies to
further investigate a suggested trend in cleaner resection margins
with the neoadjuvant strategy, but are insufficient for definitive
conclusions.
Katz et al. have recently reported the outcome from a large
series of patients with borderline resectable pancreatic adenocar-
cinoma.28 All patients were initially treated with chemotherapy
and/or chemoradiation and were subsequently restaged. The
authors report very favourable outcomes in those patients with
borderline resectable disease who underwent surgical resection
after neoadjuvant therapy. Although much smaller in numbers,
our experience with patients having borderline resectable disease
receiving neoadjuvant therapy, and subsequently undergoing
pancreatic resection, parallels the findings from the MD Anderson
study.
As a result of the near universal recurrence of pancreatic adeno-
carcinoma after surgical resection, it is imperative to question all
components of our current standard approach.26,29 This includes
the central dogma of up-front primary surgery in localized pan-
creatic adenocarcinoma patients. Neoadjuvant therapy has been
proposed as an alternative approach in patients with localized
pancreatic adenocarcinoma.29 The safety of neoadjuvant therapy
has been demonstrated in multiple, mostly single-institution,
single arm phase II studies.30–32 This study supports the argument
that the major advantage of pre-operative approach is to allow the
patients with localized pancreatic adenocarcinoma to receive all
the components of combined modality therapy. This could ulti-
mately result in better patient selection for surgical resection
and improved outcome. In addition, the neoadjuvant approach
can also result in an increase of R0 resections, particularly in
borderline resectable patients.
While analysing the outcome data from adjuvant and neoadju-
vant trials, it is crucial to realize that not all patients with resected
pancreatic adenocarcinoma will be able to receive planned adju-
vant therapy. It is very unlikely that an adequately powered clinical
trial will soon be able to definitively compare adjuvant and neo-
adjuvant approaches. We hope that our current report will fill this
gap in knowledge.
This study has a number of limitations. The cohort of patients
who received pre-operative therapy is small. There is also signifi-
cant heterogeneity among different chemotherapy regimens.
Finally the use of adjuvant therapy has evolved over the period
of study.
Despite these disadvantages, this study adds additional insight
to the outcome of patients with localized and locally advanced
pancreatic adenocarcinoma. Neoadjuvant therapy may have a
major advantage of giving the patients exposure to all compo-
nents of therapy and has a potential to improve the surgical
outcome. There is an urgent need for multi-institutional random-
ized pre-operative trials to improve the outcome of patients with
resectable pancreatic adenocarcinoma.
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